0.3502

4.23% 0.0142

After Hours: .35 -0.0002 -0.06%

Gossamer Bio Inc (GOSS)

Overview News Price History Option Chain Financials Discussions Forecast

Gossamer Bio Inc stock is traded at $0.3502, with a volume of 4.47M. It is up +4.23% in the last 24 hours and up +1.24% over the past month. Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

Previous Close:

$0.336

Open:

$0.3449

24h Volume:

4.47M

Relative Volume:

0.29

Market Cap:

$82.19M

Revenue:

$48.47M

Net Income/Loss:

$-170.37M

P/E Ratio:

-0.467

EPS:

-0.7499

Net Cash Flow:

$-171.35M

1W Performance:

+0.17%

1M Performance:

+1.24%

6M Performance:

-84.84%

1Y Performance:

-67.87%

1-Day Range:

$0.333

$0.3599

1-Week Range:

$0.3301

$0.3799

52-Week Range:

$0.32

$3.87

Gossamer Bio Inc Stock (GOSS) Company Profile

Name

Gossamer Bio Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(858) 684-1300

Address

3115 MERRYFIELD ROW, SAN DIEGO, CA

Employee

162

Twitter

@GossamerBio

Next Earnings Date

2026-05-21

Latest SEC Filings

GOSS's Discussions on Twitter

Compare GOSS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GOSS Gossamer Bio Inc	0.3502	78.86M	48.47M	-170.37M	-171.35M	-0.7499
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-23-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-24-26	Downgrade	Barclays	Overweight → Equal Weight
Feb-24-26	Downgrade	Leerink Partners	Outperform → Market Perform
Feb-24-26	Downgrade	Wedbush	Outperform → Neutral
Jan-28-26	Initiated	Barclays	Overweight
Sep-10-25	Upgrade	UBS	Neutral → Buy
Jul-14-25	Initiated	Scotiabank	Sector Outperform
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-05-24	Resumed	Wedbush	Outperform
Jul-27-23	Downgrade	UBS	Buy → Neutral
Mar-07-23	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-23	Initiated	Guggenheim	Neutral
Dec-07-22	Downgrade	Barclays	Overweight → Equal Weight
Dec-07-22	Downgrade	JP Morgan	Neutral → Underweight
Dec-07-22	Downgrade	SMBC Nikko	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Sep-21-22	Initiated	JP Morgan	Neutral
Sep-19-22	Initiated	Wedbush	Outperform
Apr-18-22	Initiated	Raymond James	Outperform
Apr-06-22	Initiated	UBS	Buy
Jan-10-22	Upgrade	SMBC Nikko	Neutral → Outperform
Nov-09-21	Resumed	Cantor Fitzgerald	Overweight
Sep-21-21	Resumed	Piper Sandler	Overweight
Jun-29-20	Initiated	H.C. Wainwright	Buy
Apr-22-20	Initiated	Piper Sandler	Overweight
Feb-27-20	Initiated	Barclays	Overweight
Dec-03-19	Resumed	BofA/Merrill	Buy
Oct-30-19	Initiated	Berenberg	Buy
Mar-05-19	Initiated	Barclays	Overweight
Mar-05-19	Initiated	BofA/Merrill	Buy
Mar-05-19	Initiated	Evercore ISI	Outperform
Mar-05-19	Initiated	SVB Leerink	Outperform

View All

Gossamer Bio Inc Stock (GOSS) Latest News

04:53 AM

INVESTOR NOTICE: Gossamer Bio, Inc. (GOSS) Investors with - GlobeNewswire

04:53 AM

01:02 AM

Deadline Alert: Gossamer Bio, Inc. (GOSS) Shareholders Who - GlobeNewswire

01:02 AM

May 05, 2026

GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit - PR Newswire

May 05, 2026